Your search returned 8 results.

Sort
Results
1.
Number of Foci of Functioning Thyroid Tissue Remaining after Thyroidectomy for Differentiated Thyroid Cancer: Institutional Experience. MedStar authors:
  • Khorjekar, Gauri
  • Kulkarni, Kanchan
  • Mete, Mihriye
  • Van Nostrand, Douglas
PMID:
  • 28553178
Year: 2017
Citation:
  • World Journal of Nuclear Medicine. 16(2):122-125, 2017 Apr-Jun
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Nuclear Medicine
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Khorjekar G, Kulkarni K, Mete M, Van Nostrand D
2.
Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?. MedStar authors:
  • Atkins, Francis
  • Burman, Kenneth
  • Garcia, Carlos
  • Khorjekar, Gauri R
  • Mete, Mihriye
  • Moreau, Shari
  • O'Neil, Jeff
  • Orquiza, Michael H
  • Van Nostrand, Douglas
  • Wartofsky, Leonard
PMID:
  • 24820222
Citation:
  • Thyroid. 24(9):1394-9, 2014 Sep.
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Endocrinology
  • Medicine/Nuclear Medicine
Medline publication type:
  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Atkins FB, Burman K, Garcia C, Khorjekar GR, Mete M, Moreau S, O'Neil J, Orquiza MH, Van Nostrand D, Wartofsky L
3.
Characterization of salivary gland side effects secondary to 131I therapy: final report of the thyroid cancer survivors' association, inc. (ThyCa) national survey for intermediate and long term results MedStar authors:
  • Hall, Jordan
  • Khorjekar, Gauri
  • Mete, Mihriye
  • Orquiza, Michael D
  • Van Nostrand, Douglas
Year: 2013
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Nuclear Medicine
Form of publication:
  • Conference
All authors:
  • Orquiza M, Hall J, Van Nostrand D, Khorjekar G, Brennan M, McIver B, Mete M, Bloom G
Local accession number:
  • 2013_7
4.
Correlation of 124I PET dosimetry with clinical response of 131I therapy (Tx) for metastatic differentiated thyroid cancer (DTC) MedStar authors:
  • Atkins, Frank
  • Garcia, Carlos
  • Khorjekar, Gauri
  • Mete, Mihriye
  • Orquiza, Michael D
  • Van Nostrand, Douglas
  • Wartofsky, Leonard
Year: 2013
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
  • Washington Cancer Institute
Department:
  • Medicine/Nuclear Medicine
Form of publication:
  • Conference
All authors:
  • Khorjekar G, Senthamizhchelvan S, Hobbs R, Orquiza M, Atkins F, Mete M, Garcia C, Wartofsky L, Sgouros G, Van Nostrand D
Local accession number:
  • 2013_4
5.
Characterization of salivary gland side effects up to 7 days after 131I therapy: final report of the thyroid cancer survivors' association, inc. (ThyCa) national survey MedStar authors:
  • Hall, Jordan
  • Khorjekar, Gauri
  • Mete, Mihriye
  • Orquiza, Michael D
Year: 2013
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Nuclear Medicine
Form of publication:
  • Conference
All authors:
  • Orquiza M, Hall J, Khorjekar G, Brennan M, McIver B, Mete M, Bloom G
Local accession number:
  • 2013_7
6.
Correlation of 124I PET dosimetry with clinical response of 131I therapy (Tx) for Metastatic Differentiated Thyroid Cancer (DTC). MedStar authors:
  • Atkins, Frank
  • Garcia, Carlos
  • Khorjekar, Gauri
  • Mete, Mihriye
  • Orquiza, Michael D
  • Van Nostrand, Douglas
  • Wartofsky, Leonard
Year: 2013
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Nuclear Medicine
Form of publication:
  • Conference
All authors:
  • Khorjekar G, Orquiza MD, Atkins F, Mete M, Garcia C, Wartofsky L, Van Nostrand D
Local accession number:
  • 2013_2
7.
Correlation of 124 I PET dosimetry with clinical response of 131 I therapy for metastatic differentiated thyroid cancer. MedStar authors:
  • Atkins, Frank
  • Garcia, Carlos
  • Khorjekar, Gauri
  • Mete, Mihriye
  • Orquiza, Michael D
  • Van Nostrand, Douglas
  • Wartofsky, Leonard
Year: 2013
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Nuclear Medicine
Form of publication:
  • Conference
All authors:
  • Khorjekar G, Senthamizhchelvan S, Hobbs R, Orquiza M, Atkins F, Mete M, Garcia C, Wartofsky L, Sgouros G, Van Nostrand D
Local accession number:
  • 2013_16
8.
Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.[Erratum appears in J Nucl Med. 2012 May;53(5):830] MedStar authors:
  • Atkins, Frank B
  • Burman, Kenneth D
  • Chennupati, Shyam P
  • Kharazi, Pejman
  • Khorjekar, Gauri R
  • Mete, Mihriye
  • Moreau, Shari
  • O'Neil, Jeff
  • Van Nostrand, Douglas
  • Wartofsky, Leonard
PMID:
  • 22315442
Year: 2012
Citation:
  • Journal of Nuclear Medicine. 53(3):359-62, 2012 Mar.
Institution:
  • MedStar Health Research Institute
  • MedStar Washington Hospital Center
Department:
  • Medicine/Endocrinology
  • Medicine/Nuclear Medicine
Medline publication type:
  • Journal Article
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Atkins FB, Burman KD, Chennupati SP, Kharazi P, Khorjekar GR, Mete M, Moreau S, O'Neil J, Van Nostrand D, Wartofsky L
Pages

Powered by Koha